Skip to main content

Table 5 Criteria for S-1 skipping and reduction of docetaxel and S-1 from the next course in the postoperative DS chemotherapy

From: Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

 

S-1 skipping

Docetaxel and S-1 reduction from the next course

Neutrophil count decreased

Grade 3

Grade 4

Platelet count decreased

Grade 3

Grade 3

Creatinine increased

>1.5 mg/dL

>1.5 mg/dL

Febrile neutropenia

Grade 3

Infection

Grade 3

Diarrhea, Oral mucositis, Rash

Grade 2

Grade 3

Nausea, Fatigue

Grade 2

Grade 3

Vomiting, Anorexia

Grade 2

Grade 3

Infusion reaction

Grade 2

Hypernatremia, Hyponatremia, Hyperkalemia, Hypokalemia

Grade 2

Grade 3

  1. DS docetaxel and S-1. Grades are written according to Common Terminology Criteria for Adverse Events (CTCAE) Version5.0